Jia-Tao Zhang
Overview
Explore the profile of Jia-Tao Zhang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
659
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zheng M, Zhou Q, Chen H, Jiang B, Tang L, Jie G, et al.
Nat Med
. 2025 Feb;
PMID: 40016451
Genomic profiling of central nervous system (CNS) metastases has the potential to guide treatments. In the present study, we included 584 patients with non-small-cell lung cancer and CNS metastases and...
2.
Zhang J, Zheng Y, Zhang H
Phys Chem Chem Phys
. 2025 Feb;
27(7):3941-3949.
PMID: 39902520
In this paper, a multilayer structure (MS) containing Weyl semimetal materials (WSM) is proposed for separating circularly polarized waves with opposite handedness. The MS configuration is optimized to maximize the...
3.
Zhang J, Liu S, Gao X, Liu S, Yan B, Huang C, et al.
Clin Cancer Res
. 2025 Jan;
PMID: 39853318
Purpose: The prognostic value of molecular residual disease (MRD) in non-small cell lung cancer (NSCLC) is well-established, with treatment-guiding results anticipated. Here, we present updated analyses from our previous published...
4.
Dong S, Yan B, Liu S, Gao X, Hong H, Li H, et al.
JTO Clin Res Rep
. 2025 Jan;
6(1):100758.
PMID: 39758595
Introduction: EGFR tyrosine kinase inhibitor (TKI) is the standard adjuvant treatment for patients with stages IB to IIIA -mutated NSCLC. Nevertheless, adapting this approach to include a molecular residual disease...
5.
Huang C, Chen Z, Peng L, Zhang J, Lin J, Zhang S, et al.
Interdiscip Cardiovasc Thorac Surg
. 2024 Dec;
40(1).
PMID: 39739332
Objectives: In recent years, with the advancement of sublobar resection, a safe, painless method for locating peripheral pulmonary nodules was needed. Previously, an alternative method of arterial watershed localization was...
6.
Li H, Qiu Z, Wang M, Zhang C, Hong H, Fu R, et al.
J Thorac Oncol
. 2024 Sep;
20(1):52-64.
PMID: 39306192
Introduction: An increasing number of early-stage lung adenocarcinomas (LUAD) are detected as lung nodules. The radiological features related to LUAD progression warrant further investigation. Exploration is required to bridge the...
7.
Dong S, Wang Z, Zhang J, Yan B, Zhang C, Gao X, et al.
JAMA Oncol
. 2024 Jun;
10(7):932-940.
PMID: 38869865
Importance: Uninterrupted targeted therapy until disease progression or intolerable toxic effects is currently the routine therapy for advanced non-small cell lung cancer (NSCLC) involving driver gene variations. However, drug resistance...
8.
Li H, Zhang J, Dong S, Yang X, Cui S, Wu Y, et al.
J Thorac Dis
. 2024 Feb;
16(1):423-429.
PMID: 38410594
Background: Carcinoembryonic antigen (CEA) has been routinely used as a postoperative monitoring biomarker for non-small cell lung cancer (NSCLC). Emergingly, circulating tumor DNA (ctDNA)-molecular residual disease (MRD) detection is a...
9.
Lack of incremental value of three-dimensional measurement in assessing invasiveness for lung cancer
Wang M, Li J, Dou S, Li H, Qiu Z, Zhang C, et al.
Eur J Cardiothorac Surg
. 2023 Nov;
64(6).
PMID: 37975876
Objectives: The aim of this study was to evaluate the performance of consolidation-to-tumour ratio (CTR) and the radiomic models in two- and three-dimensional modalities for assessing radiological invasiveness in early-stage...
10.
Zhang J, Dong S, Gu W, Zhao N, Liang Y, Tang W, et al.
Clin Lung Cancer
. 2023 Oct;
25(1):e1-e4.
PMID: 37880076
Background: The utility of circulating tumor DNA to monitor molecular residual disease (MRD) has been clinically confirmed to predict disease recurrence in non-small cell lung cancer (NSCLC) patients after radical...